Nir, Talia M. http://orcid.org/0000-0002-7106-7443
Villalón-Reina, Julio E.
Salminen, Lauren E.
Haddad, Elizabeth
Zheng, Hong
Thomopoulos, Sophia I.
Jack, Clifford R. Jr. http://orcid.org/0000-0001-7916-622X
Weiner, Michael W.
Thompson, Paul M.
Jahanshad, Neda
,
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (T32AG058507, RF1AG057892, U01AG068057, R01AG058854, R01AG059874)
Alzheimer’s Association (AARG-23-1149996, Zennith Award)
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (P41EB015922)
Alzheimer’s Association
U.S. Department of Health & Human Services | NIH | National Institute on Aging
Article History
Received: 13 February 2023
Revised: 25 October 2023
Accepted: 7 November 2023
First Online: 13 December 2023
Competing interests
: MWW has served on the scientific advisory boards for Lilly, Araclon, and Institut Catala de Neurociencies Aplicades, Gulf War Veterans Illnesses Advisory Committee, VACO, Biogen Idec, and Pfizer; has served as a consultant for Astra Zeneca, Araclon, Medivation/Pfizer, Ipsen, TauRx Therapeutics Ltd., Bayer Healthcare, Biogen Idec, Exonhit Therapeutics, SA, Servier, Synarc, Pfizer, and Janssen; has received funding for travel from NeuroVigil, Inc., CHRU-Hopital Roger Salengro, Siemens, AstraZeneca, Geneva University Hospitals, Lilly, University of California, San Diego–ADNI, Paris University, Institut Catala de Neurociencies Aplicades, University of New Mexico School of Medicine, Ipsen, CTAD (Clinical Trials on AD), Pfizer, AD PD meeting, Paul Sabatier University, Novartis, Tohoku University; has served on the editorial advisory boards for Alzheimer’s and Dementia and MRI; has received honoraria from NeuroVigil, Inc., Insitut Catala de Neurociencies Aplicades, PMDA/Japanese Ministry of Health, Labor, and Welfare, and Tohoku University; has received commercial research support from Merck and Avid; has received government research support from DOD and VA; has stock options in Synarc and Elan; and declares the following organizations as contributors to the Foundation for NIH and thus to the NIA funded AD Neuroimaging Initiative Abbott, Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation, Anonymous Foundation, AstraZeneca, Bayer Healthcare, BioClinica, Inc. (ADNI 2), Bristol-Myers Squibb, Cure Alzheimer’s Fund, Eisai, Elan, Gene Network Sciences, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Company, Medpace, Merck, Novartis, Pfizer Inc., Roche, Schering Plow, Synarc, and Wyeth. CRJ has provided consulting services for Janssen Research & Development, LLC., and Eli Lilly. MB is a former employee of GE Medical Systems and receives pension payment. CJ consults for Lily and serves on an independent data monitoring board for Roche but he receives no personal compensation from any commercial entity. CJ receives research support from NIH and the Alexander Family Alzheimer’s Disease Research Professorship of the Mayo Clinic. PMT and NJ report a research grant from Biogen, Inc. for research unrelated to this manuscript. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.